Wednesday Edition
Monday Edition
The following summarizes some of the highlights from Day 2 of the American Academy of Neurology annual meeting (AAN), Chicago, Illinois, April 18-22, 2026.
Neurology
AAN DAILY HIGHLIGHTS – MONDAY, APRIL 20, 2026
April 20, 2026Wednesday Edition
Tuesday Edition
The following summarizes some of the highlights from Day 1 of the American Academy of Neurology annual meeting (AAN), Chicago, Illinois, April 18-22, 2026.
Ultomiris (ravulizumab) now publicly reimbursed in gMG
April 7, 2026ADVERTORIAL – Sponsored by Alexion, AstraZeneca Rare Disease
PrUltomiris® (ravulizumab) now publicly reimbursed for adult anti-AchR-antibody-positive generalized myasthenia gravis in Ontario, Alberta, Nova Scotia, Saskatchewan, Newfoundland and Labrador, and NIHB
Alexion, AstraZeneca Rare Disease is pleased to announce that as of March 26, 2026, ravulizumab (Ultomiris) is listed in Ontario through the Exceptional Access Program (EAP) for the treatment of adult patients with anti-anticholinergic receptor (AChR) antibody-positive generalized myasthenia gravis (gMG). Read More
Ultomiris (ravulizumab) now publicly reimbursed in NMOSD
March 4, 2026ADVERTORIAL – Sponsored by Alexion, AstraZeneca Rare Disease
PrUltomiris® (ravulizumab) now publicly reimbursed for adult anti-AQP4 antibody-positive NMOSD in Ontario, Quebec, Alberta, Nova Scotia, Saskatchewan, and NIHB
Alexion, AstraZeneca Rare Disease is pleased to announce that as of January 20th, 2026, ravulizumab (Ultomiris) is now listed on the Ontario Drug Benefit program for the treatment of adult patients with anti-aquaporin 4 (AQP4) antibody-positive neuromyelitis optica spectrum disease (NMOSD). Read More